Jazz (JZP258-406)- An open-label, multicenter switch study evaluating changes in blood pressure in participants. Switching from high-sodium oxybate to Xywav
Diagnoses of Narcolepsy
11 weeks with about 8 visits
Jazz (JZP258-407)-Narcolepsy greater than 9-gram cohort- A Prospective, open-label, single-arm, multicenter study to evaluate the effect of low-sodium oral solution (Xywav) on sleepiness, polysomnography, and functional outcomes in adult participants
Ages 18-75
Diagnoses of Narcolepsy
10-36 weeks
Merck (MK-6552-004)- A Two-Part Study to Assess the Safety, Tolerability, Pharmacokinetics and Sleep Latency Effects of MK-6552 in Participants with Narcolepsy Type 1
Is an individual of any sex/gender, from 18 years to 55 years of age inclusive, at the time of providing the informed consent
Has a BMI between 18 and 32 kg/m2, inclusive.
Alkermes (ALKS2680-201)- A Phase 2, Parallel-Group, Dose-Range-Finding Study with Randomized Double-Blind Treatment and Open-Label Periods to Evaluate the Safety and Efficacy of ALKS 2680 in Subjects with Narcolepsy Type 1
18-70 years of age
BMI > 18 and < 35kg/m2
Obstructive Sleep Apnea Studies
Nyxoah (CL-CCC2022)- A Multicenter study to assess the safety and effectiveness of the Genro Dual Sided Hypoglossal nerve stimulation system for the treatment of obstructive sleep apnea in subjects with complete concentric collapse of the soft palate.
Ages between 22-75.
BMI is < 32kg/m2
Must have failed PAP therapy.
Lung Studies
Sanofi Asthma (LPS16676)- A randomized, double-blind, placebo-controlled study assessing the long-term effect of dupilumab on prevention of lung function decline in patients with uncontrolled moderate to severe asthma.
Must be 18
Diagnosed with asthma for > 1 year
History of > 1 severe exacerbation within the last year
No steroids within the last 1 month prior to Screening visit
Chiesi COPD (CLI-05993AA3-06)-A phase III, 52-week, multinational, multicenter, randomized, double-blind, 2-arm parallel group study comparing efficacy, safety and tolerability of the fixed dose triple combination of beclomethasone dipropionate plus formoterol fumarate plus glycopyrronium bromide (CHF 5993) with the fixed dose duel combination of beclomethasone dipropionate plus formoterol fumarate (CHF 535), both administered via pMDI.
Primary diagnosis of COPD
Male or female >40 years
COPD diagnosis for at least 12 months before screening with the definition by the GOLD report
Current or ex-smokers who quit at least 6 months prior to screening with a smoking history of at least 10 pack-years
Use of daily inhaled therapy and stable for at least 3 months
Other Studies
Idorsia (ID-078A205)- Multi-center, double-blind, randomized, placebo-controlled, parallel-group, polysomnography, dose-finding study assessing the efficacy, safety, and pharmacokinetics of multiple-dose oral administration of daridorexant in pediatric subjects aged 10 to < 18 years with insomnia disorder
